Shares of Box, Inc. (BOX) surged more than 10% in extended-hours trading Wednesday as the company delivered higher revenue and a narrower loss in its quarterly financial results.
For its first quarter fiscal 2016, BOX posted revenue of $65.6 million, a 45% increase year over year, and non-GAAP net loss of ($0.28) per share, compared to a non-GAAP net loss of ($2.32) per share in the same quarter the prior year, beating the Capital IQ Consensus Estimate of ($0.31) loss per share on revenues of $63.7 million for the period.
BOX has raised its revenue guidance for the full year fiscal 2016 to a range of $286 million to $290 million from the previous guidance of $281 million to $285 million, also exceeding the Capital IQ Consensus Estimate of $283.43 million in revenue for the period.
As the world's leading enterprise software platform for content collaboration, BOX helps businesses of all sizes in every industry securely access and manage their critical information in the cloud.
More about Box, Inc. (BOX) at www.box.com.
**
After the closing bell on Wednesday, Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc. (DRNA) in the Superior Court of Middlesex County, Massachusetts.
By this lawsuit, ALNY said that it is seeking to stop misappropriation by Dicerna of the company's confidential, proprietary, and trade secret information related to, among other things, GalNAc conjugate technology, which ALNY acquired via its buyout of Sirna Therapeutics from pharmaceutical giant Merck in January 2014.
The suit accuses Dicerna of obtaining the confidential information and trade secrets it needed to advance its research in the field of siRNA therapies and delivery technologies by hiring several of the very scientists from Merck who were involved in the research and development of the technologies purchased by ALNY
ALNY is a biopharmaceutical company developing novel therapeutics based on RNAi (RNA interference), a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.
More about Alnylam Pharmaceuticals, Inc. (ALNY) at www.alnylam.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites CRWE PR, expected to be a one-stop shop for the various needs of consumers.
The company's CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
For its first quarter fiscal 2016, BOX posted revenue of $65.6 million, a 45% increase year over year, and non-GAAP net loss of ($0.28) per share, compared to a non-GAAP net loss of ($2.32) per share in the same quarter the prior year, beating the Capital IQ Consensus Estimate of ($0.31) loss per share on revenues of $63.7 million for the period.
BOX has raised its revenue guidance for the full year fiscal 2016 to a range of $286 million to $290 million from the previous guidance of $281 million to $285 million, also exceeding the Capital IQ Consensus Estimate of $283.43 million in revenue for the period.
As the world's leading enterprise software platform for content collaboration, BOX helps businesses of all sizes in every industry securely access and manage their critical information in the cloud.
More about Box, Inc. (BOX) at www.box.com.
**
After the closing bell on Wednesday, Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc. (DRNA) in the Superior Court of Middlesex County, Massachusetts.
By this lawsuit, ALNY said that it is seeking to stop misappropriation by Dicerna of the company's confidential, proprietary, and trade secret information related to, among other things, GalNAc conjugate technology, which ALNY acquired via its buyout of Sirna Therapeutics from pharmaceutical giant Merck in January 2014.
The suit accuses Dicerna of obtaining the confidential information and trade secrets it needed to advance its research in the field of siRNA therapies and delivery technologies by hiring several of the very scientists from Merck who were involved in the research and development of the technologies purchased by ALNY
ALNY is a biopharmaceutical company developing novel therapeutics based on RNAi (RNA interference), a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.
More about Alnylam Pharmaceuticals, Inc. (ALNY) at www.alnylam.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites CRWE PR, expected to be a one-stop shop for the various needs of consumers.
The company's CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
